Across TCGA pan-cancer cohorts, LPAR5 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LPAR5 data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LPAR5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LPAR5 expression acts as an unfavorable survival marker.

LUAD and GBM are the cancer types where LPAR5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.447	1.000	.006	32	view →
GBM	OS	Tertile	All	0.246	0.650	.002	16	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: LPAR5 tumor-vs-normal RNA expression · all LPAR5 data types